Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31391906 | 0.87 | KCNH2 (0.39) | KCNH2EGFRMAP4K4SLC2A1 | |
| SCHEMBL5253770 | 0.87 | KCNH2 (0.44) | KCNH2EGFRMAP4K4SLC2A1KMT2A | |
| SCHEMBL22838577 | 0.84 | KCNH2 (0.40) | KCNH2EGFRSLC2A1 | |
| SCHEMBL1712489 | 0.81 | KCNH2 (0.42) | KCNH2SLC2A1 | |
| SCHEMBL31348085 | 0.80 | KCNH2 (0.36) | KCNH2SLC2A1 | |
| SCHEMBL5263979 | 0.80 | KCNH2 (0.48) | KCNH2SLC2A1 | |
| SCHEMBL590617 | 0.80 | KCNH2 (0.42) | KCNH2EGFRMAP4K4SLC2A1 | |
| SCHEMBL1712388 | 0.79 | KCNH2 (0.41) | KCNH2MAP4K4SLC2A1 | |
| SCHEMBL1712385 | 0.79 | KCNH2 (0.41) | KCNH2MAP4K4SLC2A1 | |
| SCHEMBL16332973 | 0.79 | KCNH2 (0.41) | KCNH2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | ENPP1, ENPP3, SMPD1 | KCNH2 4285/4885EGFR 4147/4885MAP4K4 888/4885 |
| US-20230339970-A1 | CASEIN KINASE 1 DELTA MODULATORS | CSNK1D, CSNK1A1, CSNK1G1 | KCNH2 3331/4885EGFR 1180/4885MAP4K4 122/4885 |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | ENPP1, ENPP3, SMPD1 | KCNH2 4285/4885EGFR 4147/4885MAP4K4 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.